Home › Steatotic Liver Disease › Colorado
Pag-aaral pangklinika para sa Steatotic Liver Disease sa Colorado
6 pag-aaral para sa Steatotic Liver Disease ang naghahanap ng mga kalahok sa mga site sa Colorado.
Mga Lungsod sa Colorado
Opisyal na teksto ng pag-aaral (English)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Littleton
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Littleton
Nagre-recruitPhase 3
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06318169A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- University of Colorado Anschutz Medical Campus, Aurora
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- University of Colorado Anschutz Medical Campus, Aurora
- South Denver Gastroenterology, Englewood
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Aurora
- Akero Clinical Study Site, Colorado Springs
- Akero Clinical Study Site, Englewood
Nagre-recruitPhase 3
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06528314A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Colorado Springs
Nagre-recruitPhase 3
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT07221227Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.